Alphabet Inc. is at a critical juncture, with its AI investments significantly impacting its future growth. The company faces the challenge of monetizing AI across its Search, Cloud, and YouTube platforms to justify increasing capital expenditures and address regulatory pressures. This comprehensive report scrutinizes Alphabet's business model, competitive landscape, and analyst perspectives, particularly for U.S. and English-speaking market investors, highlighting the delicate balance between innovation, cost, and competitive execution.

Moderna announced positive Phase 1/2 data for its investigational cancer antigen therapy mRNA-4359 in combination with pembrolizumab for melanoma patients, reporting an 83% overall response rate and 92% disease control rate in a small 12-patient cohort. The FDA has granted Fast Track designation for this combination in CPI-refractory PD-L1+ melanoma, and the full data will be presented at the 2026 AACR Annual Meeting. Despite the small sample size, these early results are encouraging and suggest the potential of mRNA technology in oncology.

Moody's Ratings expects major U.S. financial exchanges to report higher first-quarter revenues due to increased market volatility driven by the conflict in the Middle East. The four largest exchange operators, including CME Group and Nasdaq Inc., are anticipated to see a significant surge in net transaction and clearing fees. This rise is attributed to record trading volumes across nearly all asset classes, especially cash equities and exchange-traded derivatives, as renewed uncertainty fueled market activity.

Affiliated Managers Group (AMG) saw its shares tick lower by 1.5% following a short call from hedge fund Orso Partners, as reported by Bloomberg. Orso Partners has taken a short position in the company, leading to the decline in AMG's stock price.

This article lists ten materials stocks that experienced significant movement during Friday's intraday trading session. It highlights both gainers and losers, including Critical Metals, Lifezone Metals, and Guardian Metal Resources among those moving upwards, and LyondellBasell Industries, Dow, and LSB Industries among those that declined. Each mentioned stock includes its ticker, current price, percentage change, and market capitalization.

Shares of ScanSource (SCSC), Jabil (JBL), and Lumen (LUMN) all jumped significantly after Iran announced the reopening of the Strait of Hormuz. This news eased international tensions, boosting corporate IT spending outlooks and improving the macroeconomic climate for IT service providers. The increased investor confidence is driven by more predictable expenses for IT firms and a "risk-on" environment for growth-oriented assets.

Shares of Meritage Homes, Taylor Morrison Home, and PulteGroup surged after oil prices dropped following Iran's announcement of reopening the Strait of Hormuz. This reduction in energy costs benefits homebuilders by maintaining margins and allowing for more competitive pricing. The news also revived hopes for Federal Reserve interest rate adjustments and encouraged potential home buyers to re-enter the market, signaling resilient long-term housing demand.

The FDA has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for adults with active psoriatic arthritis (PsA), marking it as the first and only TYK2 inhibitor for this condition. This approval expands the drug's use, as it was previously authorized for moderate-to-severe plaque psoriasis. Clinical trials demonstrated significant improvement in symptoms and inhibition of radiographic progression, with a safety profile consistent with its prior use.

JetBlue Airways stock saw a 7.89% gain today, trading at $5.95 following the debut of new nonstop Boston-Barcelona flights, which expands its transatlantic network. Despite this growth, the airline faces significant financial challenges, including a potential bankruptcy warning from its founder by 2026 and a credit downgrade from Fitch due to liquidity concerns. Technically, the stock shows bullish momentum, but overbought indicators suggest a potential consolidation phase in the near term.

Jazz Pharmaceuticals PLC stock reached an all-time high of $202.58, marking a 96.99% increase over the past year and indicating strong investor confidence. The company demonstrated operational efficiency with a 91.67% gross profit margin and analysts project earnings of $25.59 per share for fiscal 2026. This milestone is further supported by recent strong financial results, including record revenue and successful product launches, leading to positive analyst ratings and price target increases.